Biotech Co.* (Country; Symbol)

Pharma Co.

Type/Product Area

Terms/Details (Date)

Abgenix Inc. (ABGX)

Sosei Corp. Ltd. (Japan)

Agreement focusing on fully human monoclonal antibody therapies against CRTH2

The companies will co-develop antibodies against CRTH2 and additional target antigens that might be contributed; they will share development and manufacturing costs for antibody products; Abgenix will use its XenoMouse technology to generate, screen and characterize human monoclonal antibodies; Sosei will be responsible for commercialization in Japan, while Abgenix would lead commercialization in the U.S.; profits would be shared equally (3/31)

(Pink Sheets: ATISZ)

Smith & Nephew plc (UK)

Agreement for Advanced Tissue to sell additional fixed assets and intellectual property rights to the wound management unit of Smith & Nephew

The agreement covers transferring certain research and development equipment and assets related to the manufacturing of collagen; Smith & Nephew will pay Advanced Tissue $700,000 (4/29)



Schering AG (Germany)

Four-year, multi-target agreement to discover drugs for various therapeutic indications

The agreement will focus on orally available, small-molecule drugs targeting solid tumors; Schering will fund Astex's related research, providing discovery and clinical milestone payments plus sales-based royalties on approved products; Schering will be responsible for clinical development and retains an option for worldwide exclusive marketing rights for all identified compounds (5/6)

Biovation Ltd.* (UK)

F. Hoffmann-La Roche Ltd. (Switzerland)

Research agreement under which Biovation will apply its DeImmunisation technology to generate biopharmaceuticals

Biovation will receive research fees and could earn license fees, milestone payments and royalties (5/21)

CeNeS Pharmaceuticals plc (UK; LSE:CEN)

Waymade Healthcare plc (UK)

Agreement to sell Diconal, Cyclimorph and Valoid to Waymade

CeNeS received more than £9M (US$14.2M) in cash for the products, which were acquired from GlaxoWellcome in September 2000 and are sold mainly to hospitals to treat post-operative pain and/or nausea and vomiting (4/16)

Chiron Corp. (CHIR)

Novartis AG (Switzerland)

Exclusive worldwide development and commercial agreement for aerosolized cyclosporine, or ACsA

Chiron gains rights to the product, which is under evaluation for the treatment of acute rejections in lung transplant recipients (4/22)

Chiron Corp. (CHIR)

West Pharmaceutical Services Inc.

Development and worldwide licensing agreement to produce and commercialize a diphtheria and tetanus nasal vaccine using West's ChiSys nasal drug delivery technology with Chiron Vaccines, the vaccine division of Chiron

West will receive development fees and milestone payments, as well as potential royalties; Chiron will be responsible for regulatory filings, marketing and commercialization activities (3/25)

CompleGen Inc.*

Berlex Laboratories Inc. (unit of Schering AG; Germany)

Research collaboration in which CompleGen is supplying Berlex with a high-throughput assay system to discover compounds against a novel target identified by Berlex using CompleGen's XenoGene system

CompleGen has rights downstream based on discovering and commercializing useful compounds (4/8)

CyDex Inc.* (Israel)

Teva Pharmaceutical Industries Ltd.

Licensing agreement giving Teva rights to Captisol, an advanced formulation system for a peptide-based drug candidate under development for treatment of systemic lupus erythematosus

CyDex granted Teva global rights for the use of Captisol in a formulation of TV-4710 (4/30)

Cytokine PharmaSciences Inc.*

Integrity Pharmaceutical Corp.

Agreement to exclusively license U.S. rights to Cytokine's second-generation cervical ripening product to Integrity

Cytokine, which will receive an undisclosed up-front payment, milestones and royalties, will manage all clinical work before a new drug application is filed, while Integrity will share expenses (4/3)

DeCode genetics Inc. (Iceland; DCGN)

AstraZeneca plc (UK)

Agreement for AstraZeneca to purchase DeCode's RoboHTC automated protein crystallo- graphy platform

Financial terms were not disclosed (4/8)

Epimmune Inc. (EPMN)

Merck & Co. Inc.

Agreement in which Merck will evaluate Epimmune's epitopes in connection with its own technology for the development of vaccines

Merck is interested in developing the technology for multiple indications (5/1)

Evotec OAI AG (Germany; Neuer Markt:EVT)

Novartis AG (Switzerland)

Assay development and screening contract to identify drug candidates for several undisclosed targets

Further details were not disclosed (4/10)

Gene Logic Inc. (GLGC)

Novartis AG (Switzerland)

Subscription agreement for Gene Logic's toxicogenomics information product, the ToxExpress Predictive System

The multiyear agreement gives Novartis access to the full complement of reference gene expression content and predictive models within the ToxExpress Predictive System (4/21)

GlycoFi Inc.*

Baxter Healthcare Corp.

Collaboration under which Baxter will evaluate the potential of GlycoFi's fungal expression platform for the production of human therapeutic proteins

Financial terms were not disclosed (5/21)

Guilford Pharmaceuticals Inc. (GLFD)

Pfizer Inc.

Licensing agreement for Pfizer to develop Guilford's N-acetylated-alpha-linked- acidic-dipeptidase inhibitors worldwide

Pfizer agreed to pay $15M, including $5M up front and the remaining $10M by next March 31, if a lead compound is selected (5/8)

Iconix Pharmaceuticals Inc.*

Eisai Co. Ltd. (Japan)

Agreement to provide chemo-genomic profiling and analytical services

Scientists will collaborate to gain a chemogenomic understanding of Eisai's early stage drug candidates to better predict their pharmacology and toxicology before clinical development (4/14)

Idenix Pharmaceuticals Inc.*

Novartis Pharma AG (Switzerland)

Licensing agreement for Idenix's hepatitis B drug candidates, which include telbivudine and valtorcitabine

Novartis will assume global clinical development costs and will be responsible for regulatory filings outside the U.S.; the deal could be worth up to $862M; Novartis is acquiring a 51% stake in Idenix for $255M and will make a $75M up-front payment; Idenix could receive up to $357M in milestone payments; Novartis has an option to jointly develop NM283, which, if exercised, could result in another $175M in milestone payments (3/26)

Immune Network Ltd. (Canada; OTC BB: IMMFF)

NV Organon (the Netherlands)

Agreement for Immune Network to access structural and biological data and samples of 120 compounds belonging to NV Organon

If such studies generate hits, Immune Network will begin preclinical development, after which the parties would negotiate a separate collaboration or license agreement (4/28)

Flamel Technologies SA (France; FLML)

GlaxoSmithKline plc (UK)

Licensing agreement for Flamel's controlled-release Micropump technology

GlaxoSmithKline plans to develop a new formulation for an undisclosed existing product; Flamel will receive an up-front payment of $2M and additional milestone payments upon achievement of certain events, as well as royalties on product sales - payments that could range up to $45M by the end of the first year following launch (3/28)

Indevus Pharmaceuticals Inc. (IDEV)

Aventis SA (France)

Agreement giving Indevus worldwide rights to an antifungal compound

Indevus gained rights to aminocandin and is responsible for all development and commercialization activities for both intravenous and oral formulations of aminocandin on a worldwide basis; Aventis will manufacture a key component of aminocandin; Indevus will make an up-front licensing payment to Aventis, as well as milestone payments and royalties (4/23)

Jerini Peptide Technologies* (subsidiary of Jerini AG; Germany)

Bayer AG (Germany)

Agreement for Jerini to provide large libraries of peptides for high-throughput screening on specific drug targets

Bayer will use Jerini's SPOT technology; financial terms were not disclosed (5/21**)

Kalypsys Inc.*

Merck & Co. Inc.

Agreement giving Merck access to Kalypsys' high-throughput lead discovery system

The companies will collaborate to extend the system's capabilities (3/25)

Lexicon Genetics Inc. (LEXG)

Aventis Pharmaceuticals Inc.

Licensing agreement for nonexclusive rights to Lexicon's gene targeting technologies

Aventis will use the technologies in its internal research programs (4/22)

Locus Pharmaceuticals Inc.*

Speedel Group (Switzerland)

Collaboration to design and develop renin inhibitors

Locus will apply its computational technology to design small-molecule renin inhibitors for further development by Speedel, which will reimburse Locus' research costs and also make milestone and royalty payments (4/29)

Medarex Inc. (MEDX)

Pfizer Inc.

Partnership to develop fully human therapeutic antibodies

Medarex will use its UltiMAb Human Antibody Development System to generate antibodies to disease targets, and could receive license fees and milestone payments, as well as royalties (4/16)

Medivir AB to (Sweden; SSE:MVIRb)

GlaxoSmithKline plc (UK)

Licensing agreement for Medivir's MIV-210

GlaxoSmithKline paid €6M in an up-front payment; it plans to continue develop the nucleoside analogue reverse transcriptase inhibitor for HIV, in which it has begun Phase I development; GSK will make milestone payments up to €86M and gained exclusive worldwide rights to the compound except in Denmark, Finland, Iceland, Norway and Sweden; Medivir will receive undisclosed royalties on eventual sales (5/20)


MCS Micro Carrier Systems GmbH (Germany)

Agreement to speed animal testing of Morphochem's lead drug candidates

MCS will formulate new chemical compounds using what the companies described as pharmaceutically relevant and acceptable components in the delivery systems design (3/28)

Neose Technologies Inc. (NTEC)

GlaxoSmithKline plc (UK)

Agreement to license certain intellectual property rights to GlaxoSmithKline

GSK gained an exclusive license to develop, produce and sell certain human vaccines for the prevention, control or treatment of undisclosed diseases; it also has non-exclusive rights to use any other patents owned by Neose that are needed to practice its rights in the same field; Neose will receive undisclosed license fees, milestone payments and royalties (4/30)

Neurogenetics Inc.*

Eli Lilly & Co.

Licensing agreement for exclusive worldwide rights to a first-in-class molecule owned by Lilly that has demonstrated efficacy across pain models

The compound is an AMPA/Kanate receptor antagonist that has been studied in patients with migraines, chronic lower back pain and pain associated with spinal cord trauma; Lilly will receive an up-front fee, success-based milestone payments and royalties on sales (5/6)

NiKem Research Srl* (Italy)

Wyeth Pharmaceuticals

Research services agreement in which NiKem will use its medicinal chemistry know ledge to provide the synthesis of chemical compounds

The compounds will complement and diversify the tools used by Wyeth to screen potential new drug candidates (5/12)

Noven Pharmaceuticals Inc. (NOVN)

Procter & Gamble Co.

Agreement to develop new prescription transdermal delivery systems for P&G Pharmaceuticals Inc., a subsidiary of Procter & Gamble

Noven is entitled to receive up to $7.8M, payable in installments if certain development milestones are achieved (4/30)

Protein Pathways Inc.*

Merck & Co. Inc.

Research collaboration in which Merck will apply Protein Pathways' ProNexus technology to its drug discovery efforts

Financial terms were not disclosed (4/2)

Regeneron Pharmaceuticals Inc. (REGN)

Novartis AG (Switzerland)

Agreement for Regeneron's Interleukin-1 Trap technology

Novartis is paying $27M in cash and making a $48M equity investment in Regeneron through a stock purchase, with the potential for $275M more in milestone payments; profits in North America and Europe will be split, along with promotion rights; development costs in 2003 will be shared; after that, Novartis will pay pre- Phase III development expenses; Regeneron retains full rights in Japan; companies will have co-promotion rights in other regions, with Novartis getting 75% of the profits (3/28)

Serenex Inc.*

GlaxoSmithKline plc (UK)

Agreement to incorporate Serenex's chemoproteomics technologies into selected GSK drug discovery programs

The agreement provides GSK with access to Serenex's Proteome Mining and Functional Proteome Fractionation technologies to screen GSK compounds against protein targets (5/5)

SkyePharma plc (UK; SKYE; LSE:SKP)

King Pharmaceuticals Inc.

Licensing agreement to develop and commercialize a modified-release formulation of King's product Altace using SkyePharma's oral, controlled-release Geomatrix drug delivery technology

King is paying SkyePharma $1M up front, potential milestones of $6.5M, reimbursing expenses and paying royalties on sales of any resulting products (5/19)

Structural GenomiX Inc.*

Eli Lilly and Co.

Agreement to install a gene-to-structure technology for Lilly in a high-throughput structural biology facility

Structural GenomiX will apply the technology platform to certain Lilly drug targets to determine their 3-dimensional structures (4/21)

SurroMed Inc.*


Biomarker discovery agreement in which Wyeth will supply clinical samples for analysis in SurroMed's BioMarker Discovery Laboratory

SurroMed will analyze the samples using its SurroScan microvolume laser-scanning cytometry system (4/2)

Symyx Technologies Inc. (SMMX)

BP plc (UK)

Two-year research and development collaboration to discover catalysts relevant to BP's commodity chemical businesses

BP will fund Symyx's discovery efforts and has exclusive rights to commercialize resulting materials, while Symyx will receive royalties in connection with the sale of those products (3/27)

Symyx Technologies Inc. (SMMX)

Merck & Co. Inc.

Agreement for the development, purchase and license of a Discovery Tools Process Optimization Workflow for preclinical development use

Financial terms were not disclosed (4/17)

Telik Inc.

F. Hoffmann-La Roche Ltd. (Switzerland)

Collaboration to use TRAP to identify drug candidates active against a Roche pharmaceutical target

Financial terms were not disclosed (4/10)

VistaGen Therapeutics

Sanwa Kagaku Kenkyusho Co. (Japan)

Multiyear research partnership to develop stem cell-based discovery tools

VistaGen will receive up-front technology license fees, an equity investment and several years of funded research (4/8)


Aventis Pasteur (unit of Aventis SA; France)

Research, option and license agreement in which Vivalis will combine its avian stem cell platform with Aventis' Alvac canary-pox virus platform in an effort to improve large-scale production of several Alvac vaccine candidates in the fields of HIV and cancer

The companies signed an option allowing Aventis to use Vivalis stem cell lines for the production of another undisclosed virus vaccine (5/6)


Bristol-Myers Squibb Co.

Nonexclusive licensing agreement for Xenogen's realtime imaging technology accompanied by an IVIS Imaging System

Under a separate agreement, BMS will grant Xenogen a nonexclusive license to use Xenogen's real-time biophotonic imaging technology and Xenogen Bioware cells and microorganisms in its research; BMS granted Xenogen rights to use Cre-Lox for its own research, as well as to include it as a commercial service offering (5/12)

Zealand Pharma A/S* (Denmark)


Development and license agreement in which the companies will co-develop ZP123 to treat arrhythmias and other cardiovascular diseases

The companies will conduct preclinical studies, while Wyeth would conduct future clinical development; Zealand will receive research funding and milestone payments, as well as royalties (5/1)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange